(HealthDay News) — The risk for cardiovascular disease (CVD) and cardiovascular (CV) death is 22% to 44% lower among individuals with type 1 diabetes treated with lipid-lowering therapy, according to a study published in Diabetes Care.

Christel Hero, from the University of Gothenburg in Sweden, and colleagues used the Swedish National Diabetes Register to identify 24 230 individuals (2006 to 2008) with type 1 diabetes without a history of CVD. The cohort included 5387 patients treated with lipid-lowering therapy (97% statins) and 18 843 untreated, propensity-matched controls. All were followed through December 2012 (mean follow-up, 6 years).

The researchers found that the propensity score balanced all 32 covariates, with no differences between treated and untreated patients after accounting for propensity score. For treated compared with untreated patients, the hazard ratio for CV death was 0.6; all-cause death, 0.56; fatal/nonfatal stroke, 0.56; fatal/nonfatal acute myocardial infarction, 0.78; fatal/nonfatal coronary heart disease, 0.85; and fatal/nonfatal CVD, 0.77.

Continue Reading

“This observational study shows that lipid-lowering therapy is associated with 22% to 44% reduction in the risk of CVD and CV death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with lipid-lowering therapy to reduce CV risk in type 1 diabetes,” the researchers concluded.


  1. Hero C, Rawshani A, Svensson A-M, et al. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. Diabetes Care. 2016. doi:10.2337/dc15-2450.